GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Strides Pharma Science Ltd (NSE:STAR) » Definitions » Capex-to-Operating-Income

Strides Pharma Science (NSE:STAR) Capex-to-Operating-Income : 0.00 (As of Sep. 2024)


View and export this data going back to 2000. Start your Free Trial

What is Strides Pharma Science Capex-to-Operating-Income?

Capex-to-Operating-Income measures a company's investments in physical assets such as property, industrial buildings or equipment to its operating income.

Strides Pharma Science's Capital Expenditure for the three months ended in Sep. 2024 was ₹0.00 Mil. Its Operating Income for the three months ended in Sep. 2024 was ₹1,852.83 Mil.

Hence, Strides Pharma Science's Capex-to-Operating-Income for the three months ended in Sep. 2024 was 0.00.


Strides Pharma Science Capex-to-Operating-Income Historical Data

The historical data trend for Strides Pharma Science's Capex-to-Operating-Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Strides Pharma Science Capex-to-Operating-Income Chart

Strides Pharma Science Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Capex-to-Operating-Income
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.41 0.71 - 0.66 0.25

Strides Pharma Science Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Capex-to-Operating-Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Strides Pharma Science's Capex-to-Operating-Income

For the Drug Manufacturers - Specialty & Generic subindustry, Strides Pharma Science's Capex-to-Operating-Income, along with its competitors' market caps and Capex-to-Operating-Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Strides Pharma Science's Capex-to-Operating-Income Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Strides Pharma Science's Capex-to-Operating-Income distribution charts can be found below:

* The bar in red indicates where Strides Pharma Science's Capex-to-Operating-Income falls into.



Strides Pharma Science Capex-to-Operating-Income Calculation

Strides Pharma Science's Capex-to-Operating-Income for the fiscal year that ended in Mar. 2024 is calculated as

Capex-to-Operating-Income=- Capital Expenditure / Operating Income
=- (-1181.51) / 4819.62
=0.25

Strides Pharma Science's Capex-to-Operating-Income for the quarter that ended in Sep. 2024 is calculated as

Capex-to-Operating-Income=- Capital Expenditure / Operating Income
=- (0) / 1852.83
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Strides Pharma Science  (NSE:STAR) Capex-to-Operating-Income Explanation

Capex-to-Operating-Income assesses how much emphasis a company is placing upon investing in capital-intensive projects. The ratio is generally a good gauge to quantify how much focus on growth a company has. Typically, smaller companies that are still growing and expanding will have a higher Capex to Operating Income Ratio, since such businesses are likely investing more in physical assets. Lower ratios could indicate that a company has reached maturity and it is no longer pursuing aggressive growth.


Strides Pharma Science Capex-to-Operating-Income Related Terms

Thank you for viewing the detailed overview of Strides Pharma Science's Capex-to-Operating-Income provided by GuruFocus.com. Please click on the following links to see related term pages.


Strides Pharma Science Business Description

Traded in Other Exchanges
Address
Strides House, Bannerghatta Road, Bilekahalli, Bengaluru, KA, IND, 560 076
Strides Pharma Science Ltd is a specialty and generic drug manufacturer. The company focuses on developing niche and complex pharmaceutical products across therapeutic segments for regulated and emerging markets. Strides' emerging-market plan focuses on branded generics for the treatment of chronic therapies. The company considers merger and acquisition investment as a potential component of its operational growth plan for expanding its research, development, manufacturing, and marketing capabilities. The company's reportable segment are; Pharmaceutical & Bio-pharmaceutical.

Strides Pharma Science Headlines

No Headlines